Showing 1731-1740 of 3314 results for "".
- Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine Reduced Lesion Growth in Phase 2 Study in GAhttps://modernod.com/news/cognition-therapeutics-reports-topline-results-showing-oral-zervimesine-reduced-lesion-growth-in-phase-2-study-in-ga/2482793/Cognition Therapeutics reported topline results from the Phase 2 COG2201 ‘MAGNIFY’ trial of zervimesine (CT1812) in adults with geographic atrophy (GA). The results show zervimesine-treated participants had 28.6% slower GA lesion growth on average and at 18 months, and their lesi
- GATHER2 Study Shows Izervay Monthly or Every Other Month Reduced GA Lesion Growth Through 2 Yearshttps://modernod.com/news/gather2-study-shows-izervay-monthly-or-every-other-month-reduced-ga-lesion-growth-through-2-years/2481944/Astellas Pharma announced results from the GATHER2 phase 3 clinical trial, demonstrating Izervay (avacincaptad pegol intravitreal solution) continued to reduce the rate of geographic atrophy (GA) lesion growth for both every month (EM) and every-other-month (EOM) dosing vs. sham through
- New Analysis of MRI Findings Show Uplizna Reduced the Formation of Asymptomatic Optic Nerve Lesions in People with NMOSDhttps://modernod.com/news/new-analysis-of-mri-findings-show-uplizna-reduced-the-formation-of-asymptomatic-optic-nerve-lesions-in-people-with-nmosd/2481467/Horizon Therapeutics announced the presentation of new MRI imaging data from the phase 3 clinical trial showing Uplizna (inebilizumab-cdon) reduced the formation of subclinical (asymptomatic) optic nerve lesions in people with Neuromyelitis Optica Spectrum Disorder (NMOSD). These findin
- FCI Ophthalmics Announces Availability of EzyPor Polyethylene Orbital Implanthttps://modernod.com/news/fci-ophthalmics-announces-availability-of-ezypor-polyethylene-orbital-implant/2481336/FCI Ophthalmics announced the launch of EzyPor in the United States. EzyPor is a high density polyethylene orbital implant with a patented suturing platform, indicated for enucleation, evisceration, and secondary implantation. Ezyor is designed to have a smooth
- FCI Ophthalmics Announces FDA Clearance of Oculid Implantable and External Eyelid Weights for the Treatment of Lagophthalmoshttps://modernod.com/news/fci-ophthalmics-announces-fda-clearance-of-oculid-implantable-and-external-eyelid-weights-for-the-treatment-of-lagophthalmos/2480641/FCI Ophthalmics announced <
- FCI Ophthalmics Announces Availability of LacriJet for Monocanalicular Nasolacrimal Intubationhttps://modernod.com/news/fci-ophthalmics-announces-availability-of-lacrijet-for-monocanalicular-nasolacrimal-intubation/2478907/FCI Ophthalmics announced the launch of the LacriJet in the United States. It is the first, self-retaining monocanalicular nasolacrimal intubation preloaded on a single use injector, according to FCI Ophthalmics. LacriJet consists of a single use injector handpiece into which a silicone tu
- Vision Impairment Tied to Less Use of Cancer Screenings by Older Adultshttps://modernod.com/news/vision-impairment-tied-to-less-use-of-cancer-screenings-by-older-adults/2478491/Older adults with vision impairment are less likely to receive recommended breast and colon cancer screenings than peers without vision problems, a U.S. study suggests, according to a Reuters report. Researchers examined data from
- FDA Accepting Less Data, More Surrogate Endpoints in Trialshttps://modernod.com/news/fda-accepting-less-data-more-surrogate-endpoints-in-trials/2477241/Over the last four decades, the FDA has loosened its requirements for approving new drugs, increasingly accepting less data and more surrogate endpoints in clinical trials, and shortening its reviews, according to a new analysis, as reported</
- J&J Vision Presents Data Validating Improved Surgical Outcomes and Surgeon Satisfaction at ASCRShttps://modernod.com/news/johnson-johnson-vision-presents-data-validating-improved-surgical-outcomes-and-surgeon-satisfaction-across-cataract-and-refractive-portfolio-at-ascrs/2480787/Johnson & Johnson Vision will present and/or support 46 company-sponsored and investigator-led studies evaluating innovations and outcomes across its surgical portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Washington, DC, April 22-26.
- Alcon Announces Scientific Program at ASCRS 2022https://modernod.com/news/alcon-announces-scientific-program-at-ascrs-2022/2480782/Alcon will once again have a significant scientific presence at the American Society of Cataract and Refractive Surgery (ASCRS) 2022 annual meeting, taking place April 22-26 in Washington, DC. Approximately 150 abstracts feature Alcon’s leading ophthalmic products and equipment—with m